Latest stories on VRXA
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
Business Insider67 · bullishproduct/pr
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
Business Insider63 · neutralproduct/pr
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
Business Insider63 · neutralgeneral
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
Business Insider56 · neutralproduct/pr
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
StockTitan63 · neutralproduct/pr
VERAXA Biotech appoints interim CFO
Seeking Alpha50 · neutralgeneral
VRXA - Veraxa Biotech Ag Stock Price
Barchart50 · neutralgeneral
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines | VRXA Stock News
StockTitan56 · neutralproduct/pr
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program | VRXA Stock News
StockTitan63 · neutralproduct/pr
Veraxa Biotech: Post-Merger Valuation Does Not Match The Risk
Seeking Alpha32 · bearishanalyst
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
GlobeNewswire65 · bullishgeneral
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
Yahoo Top28 · bearishgeneral